Random-effect meta-analysis revealed that patients with active IBD had significantly higher levels of resistin than those in remission (SMD 1.04, 95% CI 0.65 to 1.42, p-value < 0.001, Fig. 5A) which had moderate heterogeneity (I2: 68%). This evidence concerns the gene RETN and inflammatory bowel disease.